
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1172217/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell, 2022, 185, 113-130.e15.	28.9	64
2	Analysis of antibody binding specificities in twin and SNP-genotyped cohorts reveals that antiviral antibody epitope selection is a heritable trait. Immunity, 2022, 55, 174-184.e5.	14.3	22
3	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell, 2022, 185, 1556-1571.e18.	28.9	179
4	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. Science Immunology, 2022, 7, eabo0535.	11.9	17
5	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nature Medicine, 2022, 28, 1022-1030.	30.7	34
6	mRNA-1273 vaccination protects against SARS-CoV-2–elicited lung inflammation in nonhuman primates. JCI Insight, 2022, 7, .	5.0	3
7	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. PLoS Pathogens, 2022, 18, e1010574.	4.7	6
8	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science, 2021, 371, .	12.6	49
9	Measurement of leukocyte trafficking kinetics in macaques by serial intravascular staining. Science Translational Medicine, 2021, 13, .	12.4	20
10	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. IScience, 2021, 24, 102047.	4.1	16
11	T Cells Specific for a Mycobacterial Glycolipid Expand after Intravenous Bacillus Calmette–Guérin Vaccination. Journal of Immunology, 2021, 206, 1240-1250.	0.8	18
12	Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV. PLoS ONE, 2021, 16, e0248973.	2.5	10
13	Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates. Frontiers in Immunology, 2021, 12, 627688.	4.8	3
14	Immune Trait Shifts in Association With Tobacco Smoking: A Study in Healthy Women. Frontiers in Immunology, 2021, 12, 637974.	4.8	18
15	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science, 2021, 373,	12.6	174
16	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	56
17	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nature Immunology, 2021, 22, 1306-1315.	14.5	57
18	Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science, 2021, 373, 1372-1377.	12.6	459

#	Article	IF	CITATIONS
19	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, 2021, 373, eabj0299.	12.6	244
20	Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8 <sup>+</sup> T cells drive gastrointestinal acute graft-versus-host disease. Science Translational Medicine, 2021, 13, .	12.4	39
21	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates. Science, 2021, 374, 1343-1353.	12.6	83
22	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. , 2021, 9, e003388.		23
23	Robust IgM responses following intravenous vaccination with Bacille Calmette–Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques. Nature Immunology, 2021, 22, 1515-1523.	14.5	55
24	Evaluation of the Relationship between Clonal Hematopoiesis and Severe COVID-19 Disease in Rhesus Macaques. Blood, 2021, 138, 3279-3279.	1.4	0
25	Tissue Trafficking Kinetics of Rhesus Macaque Natural Killer Cells Measured by Serial Intravascular Staining. Frontiers in Immunology, 2021, 12, 772332.	4.8	2
26	Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques. Frontiers in Immunology, 2021, 12, 810047.	4.8	3
27	Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020, 577, 95-102.	27.8	394
28	Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell. AIDS Research and Human Retroviruses, 2020, 36, 998-1009.	1.1	5
29	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	27.0	936
30	<scp>OMIPâ€068</scp> : <scp>Highâ€Dimensional</scp> Characterization of Global and <scp>Antigenâ€Specific</scp> B Cells in Chronic Infection. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 1037-1043.	1.5	12
31	The V2 loop of HIV gp120 delivers costimulatory signals to CD4 <sup>+</sup> T cells through Integrin α <sub>4</sub> β <sub>7</sub> and promotes cellular activation and infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32566-32573.	7.1	14
32	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine, 2020, 12, .	12.4	30
33	Dysregulated Antibody, Natural Killer Cell and Immune Mediator Profiles in Autoimmune Thyroid Diseases. Cells, 2020, 9, 665.	4.1	18
34	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. Journal of Virology, 2020, 94, .	3.4	8
35	OMIPâ€058: 30â€Parameter Flow Cytometry Panel to Characterize iNKT, NK, Unconventional and Conventional T Cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 946-951.	1.5	26
36	OMIPâ€060: 30â€Parameter Flow Cytometry Panel to Assess T Cell Effector Functions and Regulatory T Cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 1129-1134.	1.5	45

#	Article	IF	CITATIONS
37	Blocking α <sub>4</sub> β <sub>7</sub> integrin binding to SIV does not improve virologic control. Science, 2019, 365, 1033-1036.	12.6	31
38	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. Cell Host and Microbe, 2019, 26, 336-346.e3.	11.0	88
39	Antibody Fabâ€Fc properties outperform titer in predictive models of <scp>SIV</scp> vaccineâ€induced protection. Molecular Systems Biology, 2019, 15, e8747.	7.2	17
40	Conservation of molecular and cellular phenotypes of invariant NKT cells between humans and non-human primates. Immunogenetics, 2019, 71, 465-478.	2.4	8
41	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. Clinical Cancer Research, 2019, 25, 4945-4954.	7.0	82
42	Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate. Frontiers in Immunology, 2019, 10, 1072.	4.8	15
43	The peripheral differentiation of human natural killer T cells. Immunology and Cell Biology, 2019, 97, 586-596.	2.3	20
44	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	4.7	20
45	A high throughput lentivirus sieving assay identifies neutralization resistant Envelope sequences and predicts in vivo sieving. Journal of Immunological Methods, 2019, 464, 64-73.	1.4	2
46	A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients. OncoImmunology, 2018, 7, e1426423.	4.6	17
47	Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. Journal of Virology, 2018, 92, .	3.4	30
48	Neutralization tiers of HIV-1. Current Opinion in HIV and AIDS, 2018, 13, 128-136.	3.8	89
49	The early expansion of anergic NKG2A <sup>pos</sup> /CD56 <sup>dim</sup> /CD16 <sup>neg</sup> natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. Haematologica, 2018, 103, 1390-1402.	3.5	61
50	Geographic clonal tracking in macaques provides insights into HSPC migration and differentiation. Journal of Experimental Medicine, 2018, 215, 217-232.	8.5	32
51	A deadly dance: the choreography of host–pathogen interactions, as revealed by single-cell technologies. Nature Communications, 2018, 9, 4638.	12.8	34
52	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLoS Pathogens, 2018, 14, e1007395.	4.7	37
53	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. Nature Medicine, 2018, 24, 1590-1598.	30.7	129
54	Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7. PLoS Pathogens, 2018, 14, e1007278.	4.7	29

#	Article	IF	CITATIONS
55	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nature Medicine, 2018, 24, 847-856.	30.7	65
56	Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures. Journal of Infectious Diseases, 2018, 218, S528-S536.	4.0	17
57	Background fluorescence and spreading error are major contributors of variability in highâ€dimensional flow cytometry data visualization by tâ€distributed stochastic neighboring embedding. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 785-792.	1.5	36
58	Uncovering the Molecular Signature of Pathogenic Tissue-Infiltrating T Cells during Acute Graft-Versus-Host Disease. Blood, 2018, 132, 805-805.	1.4	0
59	Chimpanzee Adenovirus Vector Ebola Vaccine. New England Journal of Medicine, 2017, 376, 928-938.	27.0	243
60	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2711-2716.	7.1	201
61	Innate and adaptive immune traits are differentially affected by genetic and environmental factors. Nature Communications, 2017, 8, 13850.	12.8	107
62	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science, 2017, 358, 85-90.	12.6	225
63	Combined single-cell quantitation of host and SIV genes and proteins ex vivo reveals host-pathogen interactions in individual cells. PLoS Pathogens, 2017, 13, e1006445.	4.7	25
64	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS ONE, 2017, 12, e0185959.	2.5	27
65	Reconstitution of Peripheral T Cells by Tissue-Derived CCR4+ Central Memory Cells Following HIV-1 Antiretroviral Therapy. Pathogens and Immunity, 2016, 1, 260.	3.1	17
66	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathogens, 2016, 12, e1005537.	4.7	51
67	Distributions of autofluorescence after compensation: Be panglossian, fret not. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 398-402.	1.5	20
68	flow <scp>C</scp> lean: Automated identification and removal of fluorescence anomalies in flow cytometry data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 461-471.	1.5	52
69	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine, 2016, 22, 614-623.	30.7	313
70	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. Journal of Immunology, 2016, 197, 2726-2737.	0.8	34
71	Rapid development of a DNA vaccine for Zika virus. Science, 2016, 354, 237-240.	12.6	348
72	A simple tube adapter to expedite and automate thawing of viably frozen cells. Journal of Immunological Methods, 2016, 439, 74-78.	1.4	13

#	Article	IF	CITATIONS
73	Early treatment with reverse transcriptase inhibitors significantly suppresses peak plasma IFNα in vivo during acute simian immunodeficiency virus infection. Cellular Immunology, 2016, 310, 156-164.	3.0	7
74	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016, 166, 609-623.	28.9	270
75	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nature Medicine, 2016, 22, 762-770.	30.7	197
76	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2016, 16, 31-42.	9.1	187
77	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Journal of Virology, 2016, 90, 4133-4149.	3.4	22
78	Identification of human viral proteinâ€derived ligands recognized by individual MHClâ€restricted Tâ€cell receptors. Immunology and Cell Biology, 2016, 94, 573-582.	2.3	25
79	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PLoS ONE, 2016, 11, e0153484.	2.5	20
80	Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study. Journal of Virology, 2015, 89, 12388-12400.	3.4	12
81	Flow cytometry strikes gold. Science, 2015, 350, 739-740.	12.6	101
82	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet, The, 2015, 385, 1545-1554.	13.7	109
83	Filarial Infection Modulates the Immune Response to <i>Mycobacterium tuberculosis</i> through Expansion of CD4+ IL-4 Memory T Cells. Journal of Immunology, 2015, 194, 2706-2714.	0.8	16
84	The Genetic Architecture of the Human Immune System: A Bioresource for Autoimmunity and Disease Pathogenesis. Cell, 2015, 161, 387-403.	28.9	292
85	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood, 2015, 125, 2855-2864.	1.4	132
86	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. Journal of Virology, 2015, 89, 8643-8650.	3.4	42
87	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2015, 89, 8334-8345.	3.4	100
88	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, 2015, 89, 8525-8539.	3.4	35
89	IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy. Cancer Research, 2015, 75, 5187-5193.	0.9	86
90	Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. Journal of Clinical Oncology, 2015, 33, 74-82.	1.6	571

#	Article	IF	CITATIONS
91	Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. Journal of Clinical Investigation, 2015, 125, 1129-1146.	8.2	97
92	Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models. PLoS Pathogens, 2015, 11, e1005100.	4.7	13
93	Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011). PLoS ONE, 2014, 9, e91366.	2.5	23
94	Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial. PLoS ONE, 2014, 9, e106240.	2.5	5
95	A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine. Human Vaccines and Immunotherapeutics, 2014, 10, 2199-2210.	3.3	25
96	Loss of Circulating CD4 T Cells with B Cell Helper Function during Chronic HIV Infection. PLoS Pathogens, 2014, 10, e1003853.	4.7	153
97	Q and B values are critical measurements required for interâ€instrument standardization and development of multicolor flow cytometry staining panels. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 1037-1048.	1.5	31
98	Differential Impact of Magnitude, Polyfunctional Capacity, and Specificity of HIV-Specific CD8 <sup>+</sup> T Cell Responses on HIV Set Point. Journal of Virology, 2014, 88, 1819-1824.	3.4	36
99	Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. Journal of Immunological Methods, 2014, 409, 107-116.	1.4	34
100	A Conversation with Leonard and Leonore Herzenberg. Annual Review of Physiology, 2014, 76, 1-20.	13.1	5
101	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature, 2014, 505, 502-508.	27.8	140
102	Single-cell technologies for monitoring immune systems. Nature Immunology, 2014, 15, 128-135.	14.5	337
103	Use of Enzyme-digested Virus-like Particles as Probes for Flow Cytometric Sorting of HIV-specific Neutralizing Ab-producing B-cells. AIDS Research and Human Retroviruses, 2014, 30, A20-A20.	1.1	0
104	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . Journal of Virology, 2014, 88, 12669-12682.	3.4	248
105	Aerosol Vaccination with AERAS-402 Elicits Robust Cellular Immune Responses in the Lungs of Rhesus Macaques but Fails To Protect against High-Dose <i>Mycobacterium tuberculosis</i> Challenge. Journal of Immunology, 2014, 193, 1799-1811.	0.8	87
106	Mixture models for single-cell assays with applications to vaccine studies. Biostatistics, 2014, 15, 87-101.	1.5	68
107	Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature Medicine, 2014, 20, 1126-1129.	30.7	311
108	Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. Science, 2013, 341, 1359-1365.	12.6	686

#	Article	IF	CITATIONS
109	Leonard Herzenberg (1931–2013). Nature, 2013, 504, 34-34.	27.8	2
110	The who's who of <scp>T</scp> â€cell differentiation: Human memory <scp>T</scp> â€cell subsets. European Journal of Immunology, 2013, 43, 2797-2809.	2.9	785
111	Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization. Journal of Immunology, 2013, 190, 2720-2735.	0.8	99
112	Leonard Herzenberg (1931–2013): The Life of FACS. Immunity, 2013, 39, 989-991.	14.3	1
113	Highly multiplexed quantitation of gene expression on single cells. Journal of Immunological Methods, 2013, 391, 133-145.	1.4	72
114	Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nature Protocols, 2013, 8, 33-42.	12.0	181
115	Early immunologic and virologic predictors of clinical HIV-1 disease progression. Aids, 2013, 27, 697-706.	2.2	13
116	Holoendemic Malaria Exposure Is Associated with Altered Epstein-Barr Virus-Specific CD8 <sup>+</sup> T-Cell Differentiation. Journal of Virology, 2013, 87, 1779-1788.	3.4	39
117	OMIPâ€017: Human CD4 <sup>+</sup> helper Tâ€cell subsets including follicular helper cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 439-440.	1.5	68
118	Quantifying spillover spreading for comparing instrument performance and aiding in multicolor panel design. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 306-315.	1.5	98
119	DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial. PLoS ONE, 2013, 8, e59340.	2.5	71
120	Superior T memory stem cell persistence supports long-lived T cell memory. Journal of Clinical Investigation, 2013, 123, 594-9.	8.2	287
121	HLA-Class I Alleles Impact Susceptibility To EBV+ Classical Hodgkin Lymphoma By Altering EBV Latent Antigen-Specific CD8+ T-Cell Immune Hierarchies. Blood, 2013, 122, 630-630.	1.4	0
122	Virus Inhibition Activity of Effector Memory CD8 <sup>+</sup> T Cells Determines Simian Immunodeficiency Virus Load in Vaccinated Monkeys after Vaccine Breakthrough Infection. Journal of Virology, 2012, 86, 5877-5884.	3.4	37
123	Increased Memory Differentiation Is Associated with Decreased Polyfunctionality for HIV but Not for Cytomegalovirus-Specific CD8+T Cells. Journal of Immunology, 2012, 189, 3838-3847.	0.8	18
124	Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1–infected patients with immune reconstitution inflammatory syndrome. Blood, 2012, 119, 3105-3112.	1.4	91
125	Quality assurance for polychromatic flow cytometry using a suite of calibration beads. Nature Protocols, 2012, 7, 2067-2079.	12.0	128
126	RchyOptimyx: Cellular hierarchy optimization for flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 1022-1030.	1.5	53

#	Article	IF	CITATIONS
127	Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. Journal of Virology, 2012, 86, 7760-7770.	3.4	31
128	HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins. Journal of Virology, 2012, 86, 11231-11241.	3.4	61
129	Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies. Journal of Immunological Methods, 2012, 386, 10-21.	1.4	33
130	Brilliant violet fluorophores: A new class of ultrabright fluorescent compounds for immunofluorescence experiments. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 456-466.	1.5	92
131	CD4 T follicular helper cell dynamics during SIV infection. Journal of Clinical Investigation, 2012, 122, 3281-3294.	8.2	307
132	A human memory T cell subset with stem cell–like properties. Nature Medicine, 2011, 17, 1290-1297.	30.7	1,547
133	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science, 2011, 333, 1593-1602.	12.6	788
134	CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nature Medicine, 2011, 17, 1128-1131.	30.7	200
135	The Simian Immunodeficiency Virus Targets Central Cell Cycle Functions through Transcriptional Repression In vivo. PLoS ONE, 2011, 6, e25684.	2.5	3
136	Data quality in the study of the mechanisms of extracorporeal photochemotherapy. Blood, 2011, 117, 366-367.	1.4	0
137	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood, 2011, 117, 4787-4795.	1.4	165
138	Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood, 2011, 117, 4805-4815.	1.4	193
139	Heavy metal contaminants can eliminate quantum dot fluorescence. , 2011, 79A, 84-89.		20
140	Interpretation of cellular proliferation data: Avoid the panglossian. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 95-101.	1.5	191
141	SPICE: Exploration and analysis of postâ€cytometric complex multivariate datasets. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 167-174.	1.5	799
142	Highâ€throughput quantitative analysis of HIVâ€1 and SIVâ€specific ADCCâ€mediating antibody responses. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 603-612.	1.5	197
143	Multiple stained samples are not appropriate compensation controls. , 2011, 79A, 591-593.		5
144	A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open, 2011, 1, e000223-e000223.	1.9	42

#	Article	IF	CITATIONS
145	Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge. Journal of Virology, 2011, 85, 4222-4233.	3.4	176
146	Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5724-5729.	7.1	86
147	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. PLoS Pathogens, 2011, 7, e1001273.	4.7	90
148	Data analysis in flow cytometry: The future just started. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 705-713.	1.5	168
149	Good cell, bad cell: Flow cytometry reveals T ell subsets important in HIV disease. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 614-622.	1.5	63
150	Publication of optimized multicolor immunofluorescence panels. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 814-818.	1.5	57
151	OMIPâ€001: Quality and phenotype of Agâ€responsive human Tâ€cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 819-820.	1.5	26
152	OMIPâ€002: Phenotypic analysis of specific human CD8+ Tâ€cells using peptideâ€MHC class I multimers for any of four epitopes. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 821-822.	1.5	7
153	A model for harmonizing flow cytometry in clinical trials. Nature Immunology, 2010, 11, 975-978.	14.5	130
154	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. PLoS ONE, 2010, 5, e9015.	2.5	125
155	IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. Journal of Experimental Medicine, 2010, 207, 1421-1433.	8.5	81
156	Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization. Journal of Virology, 2010, 84, 630-638.	3.4	57
157	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. Journal of Virology, 2010, 84, 4998-5006.	3.4	110
158	Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood, 2010, 116, 3818-3827.	1.4	159
159	Distribution, Persistence, and Efficacy of Adoptively Transferred Central and Effector Memory-Derived Autologous Simian Immunodeficiency Virus-Specific CD8+T Cell Clones in Rhesus Macaques during Acute Infection. Journal of Immunology, 2010, 184, 315-326.	0.8	33
160	Genetic immunization in the lung induces potent local and systemic immune responses. Proceedings of the United States of America, 2010, 107, 22213-22218.	7.1	65
161	Preferential infection and depletion of <i>Mycobacterium tuberculosis</i> –specific CD4 T cells after HIV-1 infection. Journal of Experimental Medicine, 2010, 207, 2869-2881.	8.5	224
162	CCR2 Identifies a Stable Population of Human Effector Memory CD4+ T Cells Equipped for Rapid Recall Response. Journal of Immunology, 2010, 185, 6646-6663.	0.8	41

#	Article	IF	CITATIONS
163	Trafficking, Persistence, and Activation State of Adoptively Transferred Allogeneic and Autologous Simian Immunodeficiency Virus-Specific CD8+T Cell Clones during Acute and Chronic Infection of Rhesus Macaques. Journal of Immunology, 2010, 184, 303-314.	0.8	34
164	Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species. PLoS Pathogens, 2010, 6, e1000904.	4.7	106
165	Amineâ€Reactive Dyes for Dead Cell Discrimination in Fixed Samples. Current Protocols in Cytometry, 2010, 53, Unit 9.34.	3.7	71
166	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 2010, 329, 856-861.	12.6	1,600
167	Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates. Journal of Virology, 2010, 84, 10386-10394.	3.4	64
168	The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. Journal of Leukocyte Biology, 2009, 85, 88-97.	3.3	221
169	Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. Journal of Experimental Medicine, 2009, 206, 923-936.	8.5	140
170	Increased IL-15 Production Is Associated with Higher Susceptibility of Memory CD4 T Cells to Simian Immunodeficiency Virus during Acute Infection. Journal of Immunology, 2009, 182, 1439-1448.	0.8	55
171	Replication-Defective Adenovirus Vectors with Multiple Deletions Do Not Induce Measurable Vector-Specific T Cells in Human Trials. Journal of Virology, 2009, 83, 6318-6322.	3.4	31
172	Association of HIV-Specific and Total CD8+ T Memory Phenotypes in Subtype C HIV-1 Infection with Viral Set Point. Journal of Immunology, 2009, 182, 4751-4761.	0.8	75
173	Differential Association of Programmed Death-1 and CD57 with Ex Vivo Survival of CD8+ T Cells in HIV Infection. Journal of Immunology, 2009, 183, 1120-1132.	0.8	105
174	The Size of the Viral Inoculum Contributes to the Outcome of Hepatitis B Virus Infection. Journal of Virology, 2009, 83, 9652-9662.	3.4	282
175	High frequencies of resting CD4 <sup>+</sup> T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8015-8020.	7.1	45
176	Autocrine Production of $\hat{1}^2$ -Chemokines Protects CMV-Specific CD4+ T Cells from HIV Infection. PLoS Pathogens, 2009, 5, e1000646.	4.7	81
177	Flow cytometry and the future of vaccine development. Expert Review of Vaccines, 2009, 8, 779-789.	4.4	38
178	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	12.6	2
179	Emerging Concepts in the Immunopathogenesis of AIDS. Annual Review of Medicine, 2009, 60, 471-484.	12.2	499
180	High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood, 2009, 113, 2238-2244.	1.4	57

#	Article	IF	CITATIONS
181	Techniques to improve the direct ex vivo detection of low frequency antigenâ€specific CD8 <sup>+</sup> T cells with peptideâ€major histocompatibility complex class I tetramers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1001-1009.	1.5	49
182	Phenotype and function of human T lymphocyte subsets: Consensus and issues. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 975-983.	1.5	645
183	Optimizing peptide matrices for identifying Tâ€cell antigens. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1071-1078.	1.5	32
184	Polyfunctional T cell responses are a hallmark of HIVâ€2 infection. European Journal of Immunology, 2008, 38, 350-363.	2.9	216
185	T-cell quality in memory and protection: implications for vaccine design. Nature Reviews Immunology, 2008, 8, 247-258.	22.7	1,410
186	A chromatic explosion: the development and future of multiparameter flow cytometry. Immunology, 2008, 125, 441-449.	4.4	154
187	Detection of low avidity CD8+ T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. Journal of Immunological Methods, 2008, 338, 31-39.	1.4	32
188	Magnitude and Quality of Vaccine-Elicited T-Cell Responses in the Control of Immunodeficiency Virus Replication in Rhesus Monkeys. Journal of Virology, 2008, 82, 8812-8819.	3.4	38
189	IL-15 Expands Unconventional CD8ααNK1.1+ T Cells but Not Vα14Jα18+ NKT Cells. Journal of Immunology, 2008, 180, 7276-7286.	0.8	22
190	Reduced Protection from Simian Immunodeficiency Virus SIV <sub>mac251</sub> Infection Afforded by Memory CD8 <sup>+</sup> T Cells Induced by Vaccination during CD4 <sup>+</sup> T-Cell Deficiency. Journal of Virology, 2008, 82, 9629-9638.	3.4	54
191	Antiretroviral Therapy prior to Acute Viral Replication Preserves CD4 T Cells in the Periphery but Not in Rectal Mucosa during Acute Simian Immunodeficiency Virus Infection. Journal of Virology, 2008, 82, 11467-11471.	3.4	25
192	Estimating the Impact of Vaccination on Acute Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections. Journal of Virology, 2008, 82, 11589-11598.	3.4	15
193	Mucosa and vaccine-induced immune protection in nonhuman primates. Current Opinion in HIV and AIDS, 2008, 3, 387-392.	3.8	2
194	Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. Journal of Experimental Medicine, 2007, 204, 1405-1416.	8.5	428
195	A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. Journal of Infectious Diseases, 2007, 196, 1732-1740.	4.0	175
196	Estimating the Infectivity of CCR5-Tropic Simian Immunodeficiency Virus SIV mac251 in the Gut. Journal of Virology, 2007, 81, 8025-8029.	3.4	16
197	CCR5 and HIV: the less, the better. Blood, 2007, 109, 854-854.	1.4	1
198	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine, 2007, 25, 4085-4092.	3.8	134

#	Article	IF	CITATIONS
199	Optimizing a Multicolor Immunophenotyping Assay. Clinics in Laboratory Medicine, 2007, 27, 469-485.	1.4	184
200	Immunisation with BCG and recombinant MVA85A induces longâ€lasting, polyfunctional <i>Mycobacterium tuberculosis</i> â€specific CD4 <sup>+</sup> memory T lymphocyte populations. European Journal of Immunology, 2007, 37, 3089-3100.	2.9	206
201	Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nature Medicine, 2007, 13, 843-850.	30.7	1,272
202	High Avidity Leukemia-Associated Antigen-Specific CD8+ T Cells Preferentially Localize to the Bone Marrow in Patients with Myeloid Malignancies Blood, 2007, 110, 2763-2763.	1.4	0
203	Peptide-Major Histocompatibility Complex Class I Tetramers with Enhanced Coreceptor Binding Properties Enable Visualization of Low Avidity Leukemia-Associated Antigen-Specific CD8+ T Cells Blood, 2007, 110, 1343-1343.	1.4	4
204	A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial. Vaccine Journal, 2006, 13, 1267-1277.	3.1	221
205	PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. Journal of Experimental Medicine, 2006, 203, 2281-2292.	8.5	808
206	Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs. PLoS Medicine, 2006, 3, e177.	8.4	182
207	HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood, 2006, 107, 4781-4789.	1.4	1,681
208	HIV vaccines: can mucosal CD4 T cells be protected?. Current Opinion in HIV and AIDS, 2006, 1, 272-276.	3.8	0
209	Acute HIV infection: it takes more than guts. Current Opinion in HIV and AIDS, 2006, 1, 10-15.	3.8	8
210	Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nature Medicine, 2006, 12, 972-977.	30.7	349
211	Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression. Nature Protocols, 2006, 1, 1-6.	12.0	197
212	Quality assurance for polychromatic flow cytometry. Nature Protocols, 2006, 1, 1522-1530.	12.0	178
213	Intracellular cytokine optimization and standard operating procedure. Nature Protocols, 2006, 1, 1507-1516.	12.0	238
214	Amine reactive dyes: An effective tool to discriminate live and dead cells in polychromatic flow cytometry. Journal of Immunological Methods, 2006, 313, 199-208.	1.4	190
215	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIVâ€1 Candidate Vaccine Delivered by a Replicationâ€Defective Recombinant Adenovirus Vector. Journal of Infectious Diseases, 2006, 194, 1638-1649.	4.0	283
216	Infectious Molecular Clones from a Simian Immunodeficiency Virus-Infected Rapid-Progressor (RP) Macaque: Evidence of Differential Selection of RP-Specific Envelope Mutations In Vitro and In Vivo. Journal of Virology, 2006, 80, 1463-1475.	3.4	27

#	Article	IF	CITATIONS
217	Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. Journal of Experimental Medicine, 2006, 203, 1533-1541.	8.5	169
218	Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. Journal of Experimental Medicine, 2006, 203, 1249-1258.	8.5	270
219	Alpha and Lambda Interferon Together Mediate Suppression of CD4 T Cells Induced by Respiratory Syncytial Virus. Journal of Virology, 2006, 80, 5032-5040.	3.4	101
220	Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. Journal of Experimental Medicine, 2006, 203, 2865-2877.	8.5	293
221	A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nature Medicine, 2005, 11, 1113-1117.	30.7	293
222	Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature, 2005, 434, 1093-1097.	27.8	1,161
223	Immunocompetent T-Cells with a Memory-Like Phenotype are the Dominant Cell Type Following Antibody-Mediated T-Cell Depletion. American Journal of Transplantation, 2005, 5, 465-474.	4.7	435
224	HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15190-15194.	7.1	323
225	Characterization of subsets of CD4+ memory T cells reveals early branched pathways of T cell differentiation in humans. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7916-7921.	7.1	91
226	Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. Journal of Experimental Medicine, 2005, 202, 1349-1361.	8.5	360
227	Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4512-4517.	7.1	126
228	Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8000-8005.	7.1	96
229	T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis. Journal of Virology, 2004, 78, 1160-1168.	3.4	351
230	Vaccination in Humans Generates Broad T Cell Cytokine Responses. Journal of Immunology, 2004, 173, 5372-5380.	0.8	186
231	Ontogeny of γÎ′T Cells in Humans. Journal of Immunology, 2004, 172, 1637-1645.	0.8	163
232	The Functional Profile of Primary Human Antiviral CD8+ T Cell Effector Activity Is Dictated by Cognate Peptide Concentration. Journal of Immunology, 2004, 172, 6407-6417.	0.8	120
233	Diversity and Recognition Efficiency of T Cell Responses to Cancer. PLoS Medicine, 2004, 1, e28.	8.4	82
234	Seventeen-colour flow cytometry: unravelling the immune system. Nature Reviews Immunology, 2004, 4, 648-655.	22.7	918

#	Article	IF	CITATIONS
235	A Potent Anti-HIV Immunotoxin Blocks Spreading Infection by Primary HIV Type 1 Isolates in Multiple Cell Types. AIDS Research and Human Retroviruses, 2004, 20, 145-150.	1.1	10
236	Flow cytometric analysis of vaccine responses: how many colors are enough?. Clinical Immunology, 2004, 110, 199-205.	3.2	65
237	Highly Tissue Substructure-Specific Effects of Human Papilloma Virus in Mucosa of HIV-Infected Patients Revealed by Laser-Dissection Microscopy-Assisted Gene Expression Profiling. American Journal of Pathology, 2004, 165, 707-718.	3.8	22
238	Guidelines for the Presentation of Flow Cytometric Data. Methods in Cell Biology, 2004, 75, 241-256.	1.1	21
239	T-cell dynamics during acute SIV infection. Aids, 2004, 18, 13-23.	2.2	59
240	Biohazard Sorting. Methods in Cell Biology, 2004, 75, 221-240.	1.1	2
241	Optimized determination of T cell epitope responses. Journal of Immunological Methods, 2003, 274, 221-228.	1.4	58
242	Optimized lymphocyte isolation methods for analysis of chemokine receptor expression. Journal of Immunological Methods, 2003, 279, 199-207.	1.4	60
243	Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. Journal of Immunological Methods, 2003, 281, 65-78.	1.4	1,424
244	Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature, 2003, 424, 681-684.	27.8	436
245	Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nature Medicine, 2003, 9, 1377-1382.	30.7	386
246	Beyond six colors: A new era in flow cytometry. Nature Medicine, 2003, 9, 112-117.	30.7	194
247	Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses. Journal of Immunology, 2003, 171, 4320-4328.	0.8	285
248	Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood, 2003, 101, 2711-2720.	1.4	887
249	Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells. Journal of Virology, 2002, 76, 4810-4821.	3.4	106
250	Role of antigen receptor affinity in T cell–independent antibody responses in vivo. Nature Immunology, 2002, 3, 399-406.	14.5	236
251	Role of BCR affinity in T cell–dependent antibody responses in vivo. Nature Immunology, 2002, 3, 570-575.	14.5	264
252	The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clinical Chemistry, 2002, 48, 1819-27.	3.2	191

#	Article	IF	CITATIONS
253	HIV-1 Actively Replicates in Naive CD4+ T Cells Residing within Human Lymphoid Tissues. Immunity, 2001, 15, 671-682.	14.3	215
254	Increased CD95/Fas-Induced Apoptosis of HIV-Specific CD8+ T Cells. Immunity, 2001, 15, 871-882.	14.3	146
255	11-color, 13-parameter flow cytometry: Identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nature Medicine, 2001, 7, 245-248.	30.7	421
256	Direct Functional Analysis of Epitope-Specific CD8+T Cells in Peripheral Blood. Viral Immunology, 2001, 14, 59-69.	1.3	52
257	A practical approach to multicolor flow cytometry for immunophenotyping. Journal of Immunological Methods, 2000, 243, 77-97.	1.4	414
258	Single Cell Analysis and Selection of Living Retrovirus Vector-corrected Mucopolysaccharidosis VII Cells Using a Fluorescence-activated Cell Sorting-based Assay for Mammalian β-Glucuronidase Enzymatic Activity. Journal of Biological Chemistry, 1999, 274, 657-665.	3.4	15
259	Differential representations of memory T cell subsets are characteristic of polarized immunity in leprosy and atopic diseases. International Immunology, 1999, 11, 1801-1810.	4.0	51
260	Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Medicine, 1999, 5, 677-685.	30.7	1,033
261	Getting to the HAART of T cell dynamics. Nature Medicine, 1998, 4, 145-146.	30.7	76
262	Dynamics of fine T-cell subsets during HIV disease and after thymic ablation by mediastinal irradiation. Seminars in Immunology, 1997, 9, 389-396.	5.6	41
263	Elevation of plasma thioredoxin levels in HIV-infected individuals. International Immunology, 1996, 8, 603-611.	4.0	188
264	Changes in antigen densities on leukocyte subsets correlate with progression of HIV disease. International Immunology, 1996, 8, 1-11.	4.0	41
265	T-cell dynamics of immunodeficiency. Nature Medicine, 1995, 1, 621-622.	30.7	74
266	Glutathione Precursor and Antioxidant Activities of N-Acetylcysteine and Oxothiazolidine Carboxylate Compared in in Vitro Studies of HIV Replication. AIDS Research and Human Retroviruses, 1994, 10, 961-967.	1.1	54
267	Disregulation of Leukocyte Glutathione in AIDS. Annals of the New York Academy of Sciences, 1993, 677, 113-125.	3.8	33
268	Antioxidants Inhibit Stimulation of HIV Transcription. AIDS Research and Human Retroviruses, 1993, 9, 299-306.	1.1	121
269	N-Acetylcysteine: Potential for AIDS Therapy. Pharmacology, 1993, 46, 121-129.	2.2	54
270	<i>N</i> -Acetylcysteine: A New Approach to Anti-HIV Therapy. AIDS Research and Human Retroviruses, 1992, 8, 209-217.	1.1	150

#	Article	IF	CITATIONS
271	Intracellular Glutathione Levels in T Cell Subsets Decrease in HIV-Infected Individuals. AIDS Research and Human Retroviruses, 1992, 8, 305-311.	1.1	163
272	Glutathione and Immunophenotypes of T and B Lymphocytes in HIV-Infected Individualsa. Annals of the New York Academy of Sciences, 1992, 651, 453-463.	3.8	22
273	N-Acetylcysteine Inhibits Latent HIV Expression in Chronically Infected Cells. AIDS Research and Human Retroviruses, 1991, 7, 563-567.	1.1	70
274	CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses. International Immunology, 1991, 3, 933-937.	4.0	142
275	Flow cytometry dna ploidy analysis and catecholamine secretion profiles in neuroblastoma. Cancer, 1990, 63, 1752-1756.	4.1	20
276	Flow cytometric DNA analysis of Neuroblastoma and Ganglioneuroma. A 10-year retrospective study. Cancer, 1988, 62, 749-754.	4.1	110
277	Flow cytometric DNA analysis of adrenocortical tumors in children. Cancer, 1987, 59, 2059-2063.	4.1	42
278	Kinetics and temperature dependence of exposure of endocytosed material to proteolytic enzymes and low pH: Evidence for a maturation model for the formation of lysosomes. Journal of Cellular Physiology, 1987, 131, 200-209.	4.1	132